Study of the Anti-FGF23 Antibody, Burosumab, in Adults With XLH

NCT03920072 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

35

Enrollment

INDUSTRY

Sponsor class

Conditions

X-linked Hypophosphatemia

Interventions

DRUG: Burosumab

Sponsor

Kyowa Kirin Pharmaceutical Development Ltd